Dr. Lal PathLabs Limited (NSE: LALPATHLAB)
India
· Delayed Price · Currency is INR 3,053.65
+27.55 (0.91%)
Nov 22, 2024, 3:29 PM IST
Dr. Lal PathLabs Revenue
Dr. Lal PathLabs had revenue of 6.60B INR in the quarter ending September 30, 2024, with 9.80% growth. This brings the company's revenue in the last twelve months to 23.46B, up 10.54% year-over-year. In the fiscal year ending March 31, 2024, Dr. Lal PathLabs had annual revenue of 22.27B with 10.40% growth.
Revenue (ttm)
23.46B
Revenue Growth
+10.54%
P/S Ratio
10.83
Revenue / Employee
5.72M
Employees
4,099
Market Cap
254.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 22.27B | 2.10B | 10.40% |
| Mar 31, 2023 | 20.17B | -705.26M | -3.38% |
| Mar 31, 2022 | 20.87B | 5.06B | 32.01% |
| Mar 31, 2021 | 15.81B | 2.51B | 18.86% |
| Mar 31, 2020 | 13.30B | 1.27B | 10.55% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDr. Lal PathLabs News
- 4 weeks ago - Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls - Business Upturn
- 4 weeks ago - Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying - Business Upturn
- 4 weeks ago - UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price - Business Upturn
- 4 weeks ago - Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore - Business Upturn
- 4 weeks ago - Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720 - Business Upturn